Syneos Health shared a post on LinkedIn:
“Following the Society of Gynecologic Oncology Annual Meeting in San Juan, the conversation in ovarian cancer is shifting from data to strategy and execution.
Muaiad Kittaneh Global Head of RandD and Scientific Strategy at Syneos Health, shares reflections on the evolving landscape – from ADCs reshaping treatment to the growing focus on sequencing, biomarkers beyond HRD and the role of MRD and ctDNA.
With a rapidly advancing pipeline, success will depend on how effectively we design trials, select patients and simplify execution.